Literature DB >> 17290266

Orexins: looking forward to sleep, back at addiction.

Thomas E Scammell, Clifford B Saper.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17290266      PMCID： PMC3058782          DOI： 10.1038/nm0207-126

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  15 in total

1.  Promotion of sleep by targeting the orexin system in rats, dogs and humans.

Authors:  Catherine Brisbare-Roch; Jasper Dingemanse; Ralf Koberstein; Petra Hoever; Hamed Aissaoui; Susan Flores; Celia Mueller; Oliver Nayler; Joop van Gerven; Sanne L de Haas; Patrick Hess; Changbin Qiu; Stephan Buchmann; Michael Scherz; Thomas Weller; Walter Fischli; Martine Clozel; François Jenck
Journal:  Nat Med       Date:  2007-01-28       Impact factor: 53.440

2.  Fos expression in orexin neurons varies with behavioral state.

Authors:  I V Estabrooke; M T McCarthy; E Ko; T C Chou; R M Chemelli; M Yanagisawa; C B Saper; T E Scammell
Journal:  J Neurosci       Date:  2001-03-01       Impact factor: 6.167

3.  Concomitant loss of dynorphin, NARP, and orexin in narcolepsy.

Authors:  A Crocker; R A España; M Papadopoulou; C B Saper; J Faraco; T Sakurai; M Honda; E Mignot; T E Scammell
Journal:  Neurology       Date:  2005-09-14       Impact factor: 9.910

4.  A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.

Authors:  C Peyron; J Faraco; W Rogers; B Ripley; S Overeem; Y Charnay; S Nevsimalova; M Aldrich; D Reynolds; R Albin; R Li; M Hungs; M Pedrazzoli; M Padigaru; M Kucherlapati; J Fan; R Maki; G J Lammers; C Bouras; R Kucherlapati; S Nishino; E Mignot
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

5.  Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine.

Authors:  Minoru Narita; Yasuyuki Nagumo; Seiko Hashimoto; Michiko Narita; Junaidi Khotib; Mayumi Miyatake; Takeshi Sakurai; Masashi Yanagisawa; Tomoya Nakamachi; Seiji Shioda; Tsutomu Suzuki
Journal:  J Neurosci       Date:  2006-01-11       Impact factor: 6.167

6.  Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation.

Authors:  R M Chemelli; J T Willie; C M Sinton; J K Elmquist; T Scammell; C Lee; J A Richardson; S C Williams; Y Xiong; Y Kisanuki; T E Fitch; M Nakazato; R E Hammer; C B Saper; M Yanagisawa
Journal:  Cell       Date:  1999-08-20       Impact factor: 41.582

7.  A role for lateral hypothalamic orexin neurons in reward seeking.

Authors:  Glenda C Harris; Mathieu Wimmer; Gary Aston-Jones
Journal:  Nature       Date:  2005-08-14       Impact factor: 49.962

8.  Expression of a poly-glutamine-ataxin-3 transgene in orexin neurons induces narcolepsy-cataplexy in the rat.

Authors:  Carsten T Beuckmann; Christopher M Sinton; S Clay Williams; James A Richardson; Robert E Hammer; Takeshi Sakurai; Masashi Yanagisawa
Journal:  J Neurosci       Date:  2004-05-05       Impact factor: 6.167

Review 9.  Hypocretin (orexin): role in normal behavior and neuropathology.

Authors:  Jerome M Siegel
Journal:  Annu Rev Psychol       Date:  2004       Impact factor: 24.137

10.  Reduced number of hypocretin neurons in human narcolepsy.

Authors:  T C Thannickal; R Y Moore; R Nienhuis; L Ramanathan; S Gulyani; M Aldrich; M Cornford; J M Siegel
Journal:  Neuron       Date:  2000-09       Impact factor: 17.173
View more
  8 in total

1.  Neural mechanism for hypothalamic-mediated autonomic responses to light during migraine.

Authors:  Rodrigo Noseda; Alice J Lee; Rony-Reuven Nir; Carolyn A Bernstein; Vanessa M Kainz; Suzanne M Bertisch; Catherine Buettner; David Borsook; Rami Burstein
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-26       Impact factor: 11.205

2.  Addiction and Sleep Disorders.

Authors:  Jonathan Ek; William Jacobs; Brett Kaylor; W Vaughn McCall
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.

Authors:  Hong Sun; William P Kennedy; Darren Wilbraham; Nicole Lewis; Nicole Calder; Xiaodong Li; Junshui Ma; Ka Lai Yee; Susan Ermlich; Eric Mangin; Christopher Lines; Laura Rosen; Jeffrey Chodakewitz; Gail M Murphy
Journal:  Sleep       Date:  2013-02-01       Impact factor: 5.849

4.  Radiosynthesis and evaluation of [11C]EMPA as a potential PET tracer for orexin 2 receptors.

Authors:  Changning Wang; Christian K Moseley; Stephen M Carlin; Colin M Wilson; Ramesh Neelamegam; Jacob M Hooker
Journal:  Bioorg Med Chem Lett       Date:  2013-04-02       Impact factor: 2.823

Review 5.  The orexins/hypocretins and schizophrenia.

Authors:  Ariel Y Deutch; Michael Bubser
Journal:  Schizophr Bull       Date:  2007-08-28       Impact factor: 9.306

6.  Dexamethasone Chemotherapy Does Not Disrupt Orexin Signaling.

Authors:  David E Kram; Stephanie M Krasnow; Peter R Levasseur; Xinxia Zhu; Linda C Stork; Daniel L Marks
Journal:  PLoS One       Date:  2016-12-20       Impact factor: 3.240

7.  Sleep disturbance as a therapeutic target to improve opioid use disorder treatment.

Authors:  Andrew S Huhn; Patrick H Finan
Journal:  Exp Clin Psychopharmacol       Date:  2021-06-10       Impact factor: 3.157

8.  Pharmacotherapy of insomnia with ramelteon: safety, efficacy and clinical applications.

Authors:  Seithikurippu R Pandi-Perumal; D Warren Spence; Joris C Verster; Venkatramanujam Srinivasan; Gregory M Brown; Daniel P Cardinali; Rüdiger Hardeland
Journal:  J Cent Nerv Syst Dis       Date:  2011-04-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.